T0	Disease 95 103	diabetes
#1	AnnotatorNotes T0	not found
T1	Chemical 215 219	DOPA
T10	Chemical 1119 1122	NAS
T11	Chemical 1136 1145	melatonin
T12	Chemical 1195 1199	5-HT
T13	Disease 1232 1240	diabetes
T14	Chemical 1379 1393	catecholamines
T15	Disease 1395 1422	Diabetes-induced neuropathy
#8	AnnotatorNotes T15	not found
T17	Chemical 1475 1483	tyrosine
T18	Drug 1509 1523	streptozotocin
T19	Disease 1509 1540	streptozotocin-induced diabetes
T2	Disease 258 266	diabetic
#13	AnnotatorNotes T2	not found
T20	Chemical 1755 1769	catecholamines
T21	Disease 1799 1807	diabetes
T3	Chemical 327 332	DOPAC
T4	Chemical 406 409	VMA
T5	Disease 459 467	diabetic
T6	Drug 536 550	streptozotocin
T7	Disease 536 567	streptozotocin-induced diabetes
#20	AnnotatorNotes T7	not found
T8	Drug 720 734	streptozotocin
T9	Disease 720 751	streptozotocin-induced diabetes
T22	Biomarker 183 254	level of NE and its precursors, DOPA and DA, were significantly reduced
T23	Chemical 192 194	NE
T24	Chemical 224 226	DA
R1	Association Arg1:T22 Arg2:T2	
T25	Chemical 350 352	DA
T26	Biomarker 316 372	content of DOPAC, a metabolite of DA, was also decreased
T27	Chemical 427 429	NE
T28	Biomarker 397 455	level of VMA, a metabolite of NE, was significantly higher
R2	Association Arg1:T28 Arg2:T5	
#2	AnnotatorNotes T6	CHEMBL1651906
T29	Chemical 876 878	NE
T30	Biomarker 936 958	increased level of VMA
T31	Chemical 955 958	VMA
T32	Chemical 985 987	NE
T33	Chemical 1019 1021	NE
T16	Gene-Protein 1475 1495	tyrosine hydroxylase
T34	Chemical 1564 1566	NE
T35	Biomarker 1553 1597	content of NE was lower in the pineal glands
T36	Disease 1601 1609	diabetic
R3	Association Arg1:T35 Arg2:T36	
R4	Association Arg1:T26 Arg2:T2	
T37	Biomarker 865 891	release of NE is augmented
